SARS-CoV-2 (2019-nCoV, COVID-19) Antigens
The newly identified coronavirus, SARS-CoV-2 (2019-nCoV), has led to pneumonia (COVID-19) that sickened over 40,000 people in China. The medical community fears that this outbreak may be on its way to become a global pandemic in the near future, if not controlled soon.
To aid the efforts of developing vaccines and neutralizing antibodies against this virus, Sino Biological Inc. has developed a panel of recombinant antigens for this new coronavirus, including the N (nucleocapsid) protein, S protein, the S1 and S2 subunits of the S protein, and the RBD domain of the S proteins, and antibodies that recognize the S protein.
Beijing Wantai has also released a brand new ELISA kit for Total Antibody and IgM Antibody against SARS-CoV-2 Virus (COVID-19).
- Sandwich method gives 93.1% sensitivity and 100% specificity
- Positive results in low viral load specimens
- PCR false negative can be detected
- Faster results vs. PCR